NEWTON, Mass., May 4, 2026
Satellite Bio announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to its investigational off-the-shelf liver therapy SB-101 for the treatment of urea cycle disorders (UCDs). The designation recognizes the urgent need for innovative therapies targeting these rare, life-threatening inherited metabolic disorders, which primarily affect infants and children and currently have no curative treatment available during the critical first weeks of life. SB-101 is being developed as a first-in-class liver cell therapy designed to restore essential metabolic liver function by delivering healthy liver cells capable of replacing lost hepatic activity. The FDA designation supports the program’s clinical development while highlighting the significant unmet medical need in patients with severe early-onset UCDs. Satellite Bio plans to initiate a Phase 1/2 clinical trial of SB-101 during 2026, marking an important milestone in advancing regenerative therapies for pediatric liver diseases.
SB-101 Designed to Restore Liver Function in Infants with Severe UCDs
Urea cycle disorders are devastating inherited metabolic diseases caused by defects in the body’s ability to remove ammonia, leading to toxic accumulation that can rapidly result in encephalopathy, seizures, coma, organ failure, severe neurological injury, and death. Current treatment options remain limited and largely supportive, with mortality exceeding 25% and approximately half of surviving patients experiencing long-term cognitive impairment. SB-101 aims to address the underlying cause of these disorders by delivering healthy functional liver cells that restore essential metabolic processes rather than simply managing symptoms. Manufactured using Satellite Bio’s proprietary scalable cell expansion platform, the therapy is designed as an off-the-shelf, cryopreserved product that is readily available when urgently needed, offering potential advantages in availability, manufacturing consistency, and cost compared with conventional individualized cell therapies. The company believes this approach could provide critically needed early intervention for infants at the highest risk of irreversible neurological damage.
Off-the-Shelf Liver Cell Platform Supports Broader Regenerative Medicine Strategy
Satellite Bio’s technology platform focuses on restoring cellular liver function, recognizing that the liver performs more than 500 essential physiological functions, including detoxification, nutrient metabolism, and production of vital blood proteins. Instead of replacing the entire organ, the company’s therapies are designed to introduce healthy liver cells into receptive sites within the body where they can engraft, survive, and restore metabolic function. The proprietary manufacturing process enables large-scale production, allowing therapies to be manufactured in advance and stored until needed, an approach intended to improve accessibility for patients with acute or chronic liver diseases. Beyond SB-101, Satellite Bio is developing additional investigational therapies targeting other pediatric liver disorders as well as chronic liver diseases in adults, expanding the potential applications of its regenerative medicine platform across multiple areas of hepatic insufficiency.
Advertisement
FDA Designation Strengthens Development Path for SB-101
The Rare Pediatric Disease designation is granted by the FDA to investigational therapies intended to treat serious or life-threatening diseases that primarily affect children from birth through 18 years of age. In addition to recognizing the significant unmet medical need, the designation may make Satellite Bio eligible to receive a Priority Review Voucher (PRV) if SB-101 ultimately receives regulatory approval, providing additional strategic value for the company. Satellite Bio believes the designation reinforces the therapeutic promise of SB-101 as a potentially transformative treatment capable of restoring liver function during the earliest stages of life, when intervention may be critical to preventing irreversible neurological injury. As the company advances toward clinical evaluation, SB-101 represents a novel regenerative medicine approach with the potential to redefine treatment for urea cycle disorders and establish a broader platform for treating severe liver diseases through off-the-shelf cell therapy.
Source:Satellite Bio press release
